A5064746430- Cancer Immunotherapy and Biomarkers
- Histone Deacetylase Inhibitors Research
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- RNA Research and Splicing
- Immune cells in cancer
- Cancer, Stress, Anesthesia, and Immune Response
National Cheng Kung University
2018
Immune checkpoint inhibitors (ICIs) have shown clinical benefit in solid tumors, with modest rates of response. Hence, improved therapeutic approaches need to be investigated. Herein, we assessed a combination chidamide plus celecoxib (called CC-01) combined programmed cell death protein 1 (PD-1) blockade CT26 model as potent tumor microenvironment (TME) regulator. The antitumor activity was by measuring size, overall response rate, and survival rate. profiling tumor-infiltrating lymphocytes...
Combined inhibition of vascular endothelial growth factor receptor (VEGFR) and the programmed cell death protein 1 (PD-1) pathways has shown efficacy in multiple cancers; however, clinical outcomes show limited benefits unmet needs still remain require improvement efficacy. Using murine colon carcinoma (CT26) allograft models, we examined elucidated novel tumor microenvironment (TME) remodeling mechanisms underlying combination chidamide (a benzamide-based class l histone deacetylase...